BELLEVUE, Wash.--(BUSINESS WIRE)--Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support, today announced it has co-developed a pediatric pharmacogenomics (PGx) solution in collaboration with Inova Genomics Laboratory, a CAP- and CLIA-certified clinical genomics laboratory and part of the Inova Translational Medicine Institute (ITMI) – a research and development organization at the forefront of applied genomics.
The clinical use of pediatric-based PGx lags corresponding adult applications, and evidence-based recommendations for genotype-guided dosing in pediatric patients are not well established. The newly available pediatric PGx solution and testing panel bridges this gap by evaluating seven actionable genes to determine how a pediatric patient will uniquely respond to specific prescription medications, and provides actionable prescribing information for 24 drugs. The testing panel includes genes which can influence the metabolism of anti-cancer agents, antidepressants, cardiovascular and gastrointestinal drugs, certain opioids and more.
“The Food and Drug Administration’s announcement earlier this year restricting use of all prescription medications containing codeine or tramadol in children under 12, and cautioning usage in 12 to 18 year olds with specific medical conditions, underscores the importance and value of PGx testing to identify the likely efficacy or toxicity of a medication for pediatric patients,” stated Houda Hachad, PharmD, MRes, chief science officer at TSI. “With growing evidence linking drug response to genetic variability, and with costs decreasing rapidly for an array of genomic tests – including the CYP2D6 genotype test for codeine toxicity – use of PGx testing is growing to inform pediatric prescribing and guide precise patient therapies.”
TSI’s proprietary PGx knowledge base classifies and interprets the raw genetic data from the pediatric PGx panel to generate a tailored, clinically actionable report with concise molecular intelligence and critical alerts regarding drug efficacy, toxicity, and known interactions to guide clinical decision making. The report includes educational information on the maturation trajectories of genes tested and the indications for each drug by age group. The PGx results of a single genetic test can be used to help guide treatment decisions throughout the patient’s lifetime, serving as a valuable once-in-a-lifetime resource for precision medicine.
TSI and ITMI have also collaborated on pharmacogenetic testing services in support of Inova Health System’s MediMap™ program, initially launched in early 2016 as an optional standard service for all babies born at Inova Women’s Hospital in Falls Church, Virginia. PGx results to date indicate that 97 percent of the 9,000+ newborns tested between February 2016 and September 2017 have had at least one actionable recommendation for drug dosing, and approximately 10 percent have had a critical result for codeine resulting from the patient’s rapid or poor metabolizer phenotype status.
About Translational Software, Inc.
Translational Software enables healthcare providers to realize the promise of precision medicine. We simplify complex genetic data into evidence-based actionable recommendations to deliver genomic decision support in platform agnostic formats. Our PGx knowledge base and Fast Healthcare Interoperability Resource (FHIR)-based API has been used to provide over one million PGx recommendations. To learn more visit us at www.TranslationalSoftware.com.